| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 14 | 2023 | 955 | 4.090 |
Why?
|
| Cardiovascular Diseases | 17 | 2023 | 2280 | 3.810 |
Why?
|
| ST Elevation Myocardial Infarction | 5 | 2024 | 141 | 3.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 12 | 2021 | 848 | 2.980 |
Why?
|
| Eicosapentaenoic Acid | 6 | 2020 | 95 | 2.720 |
Why?
|
| Heart Failure | 12 | 2024 | 2496 | 2.700 |
Why?
|
| Stroke | 7 | 2023 | 1093 | 2.190 |
Why?
|
| Cholesterol, LDL | 6 | 2022 | 576 | 2.030 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 749 | 1.940 |
Why?
|
| Troponin I | 3 | 2024 | 131 | 1.630 |
Why?
|
| Anticholesteremic Agents | 4 | 2022 | 255 | 1.610 |
Why?
|
| Dyslipidemias | 3 | 2019 | 244 | 1.580 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2023 | 83 | 1.550 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2024 | 369 | 1.300 |
Why?
|
| Coronary Disease | 3 | 2023 | 775 | 1.290 |
Why?
|
| Hypercholesterolemia | 4 | 2020 | 268 | 1.290 |
Why?
|
| Inferior Wall Myocardial Infarction | 2 | 2018 | 9 | 1.260 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 117 | 1.230 |
Why?
|
| Hypolipidemic Agents | 2 | 2020 | 190 | 1.220 |
Why?
|
| Lipids | 4 | 2019 | 659 | 1.180 |
Why?
|
| Coronary Angiography | 5 | 2024 | 568 | 1.150 |
Why?
|
| Electrocardiography | 4 | 2024 | 1192 | 1.070 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 1302 | 0.970 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2020 | 19 | 0.930 |
Why?
|
| Atrioventricular Block | 1 | 2024 | 40 | 0.900 |
Why?
|
| Brain Ischemia | 2 | 2023 | 316 | 0.900 |
Why?
|
| Myocardium | 3 | 2018 | 1250 | 0.850 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2020 | 73 | 0.810 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2024 | 331 | 0.810 |
Why?
|
| Risk Factors | 19 | 2023 | 17814 | 0.790 |
Why?
|
| Dietary Supplements | 3 | 2021 | 566 | 0.770 |
Why?
|
| Lipid Regulating Agents | 1 | 2020 | 6 | 0.740 |
Why?
|
| Ultrasonography, Interventional | 1 | 2024 | 417 | 0.740 |
Why?
|
| Natriuretic Peptide, Brain | 4 | 2023 | 339 | 0.730 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2020 | 13 | 0.720 |
Why?
|
| Vascular Stiffness | 1 | 2021 | 80 | 0.720 |
Why?
|
| Denervation | 1 | 2020 | 36 | 0.720 |
Why?
|
| Galectin 3 | 1 | 2021 | 133 | 0.710 |
Why?
|
| Cardiology | 3 | 2021 | 572 | 0.710 |
Why?
|
| Veterans | 3 | 2021 | 1764 | 0.690 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 88 | 0.670 |
Why?
|
| Troponin T | 4 | 2024 | 263 | 0.650 |
Why?
|
| Biomarkers | 9 | 2024 | 5102 | 0.650 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 4519 | 0.650 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2018 | 12 | 0.640 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2019 | 60 | 0.630 |
Why?
|
| Eligibility Determination | 1 | 2019 | 85 | 0.630 |
Why?
|
| Humans | 61 | 2024 | 270825 | 0.620 |
Why?
|
| Docosahexaenoic Acids | 1 | 2019 | 82 | 0.620 |
Why?
|
| Incretins | 1 | 2018 | 28 | 0.600 |
Why?
|
| Drug Costs | 1 | 2019 | 141 | 0.590 |
Why?
|
| Stents | 1 | 2024 | 1014 | 0.590 |
Why?
|
| Medication Adherence | 2 | 2019 | 517 | 0.580 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 163 | 0.580 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 74 | 0.580 |
Why?
|
| Secondary Prevention | 1 | 2019 | 321 | 0.580 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2022 | 2669 | 0.560 |
Why?
|
| Cardiovascular System | 1 | 2018 | 151 | 0.560 |
Why?
|
| Biological Products | 1 | 2020 | 316 | 0.560 |
Why?
|
| Anticoagulants | 3 | 2020 | 785 | 0.550 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 535 | 0.550 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 1076 | 0.540 |
Why?
|
| Risk Assessment | 6 | 2021 | 6828 | 0.510 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 945 | 0.510 |
Why?
|
| Betacoronavirus | 1 | 2020 | 520 | 0.500 |
Why?
|
| Ezetimibe | 3 | 2019 | 97 | 0.480 |
Why?
|
| United States | 16 | 2022 | 15962 | 0.480 |
Why?
|
| Pandemics | 2 | 2021 | 1596 | 0.480 |
Why?
|
| Aged | 24 | 2023 | 73188 | 0.470 |
Why?
|
| Kidney | 2 | 2020 | 2260 | 0.460 |
Why?
|
| Smoking Cessation | 1 | 2020 | 755 | 0.460 |
Why?
|
| Hypertension | 2 | 2021 | 1613 | 0.460 |
Why?
|
| Peptide Fragments | 3 | 2023 | 1327 | 0.440 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 623 | 0.440 |
Why?
|
| Hospitalization | 2 | 2019 | 2192 | 0.430 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 631 | 0.420 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 707 | 0.410 |
Why?
|
| Blood Pressure | 3 | 2024 | 1593 | 0.400 |
Why?
|
| Sitosterols | 2 | 2009 | 10 | 0.400 |
Why?
|
| Berberine | 2 | 2009 | 13 | 0.400 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2021 | 672 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 7922 | 0.390 |
Why?
|
| Myocardial Revascularization | 2 | 2024 | 135 | 0.380 |
Why?
|
| Glucosides | 3 | 2020 | 63 | 0.370 |
Why?
|
| Tobacco, Smokeless | 2 | 2020 | 29 | 0.370 |
Why?
|
| Benzhydryl Compounds | 3 | 2020 | 87 | 0.370 |
Why?
|
| Dicarboxylic Acids | 3 | 2019 | 35 | 0.360 |
Why?
|
| Middle Aged | 21 | 2023 | 90030 | 0.360 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 2083 | 0.360 |
Why?
|
| Male | 27 | 2024 | 128398 | 0.340 |
Why?
|
| Treatment Outcome | 10 | 2024 | 33821 | 0.340 |
Why?
|
| Europe | 2 | 2020 | 647 | 0.310 |
Why?
|
| Triglycerides | 3 | 2022 | 618 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1441 | 0.310 |
Why?
|
| Cholesterol | 2 | 2009 | 678 | 0.310 |
Why?
|
| Congresses as Topic | 2 | 2020 | 296 | 0.310 |
Why?
|
| Phytosterols | 1 | 2008 | 31 | 0.300 |
Why?
|
| Female | 24 | 2024 | 148456 | 0.300 |
Why?
|
| Fatty Acids | 3 | 2019 | 448 | 0.300 |
Why?
|
| Pyrimidines | 1 | 2020 | 3666 | 0.290 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 4385 | 0.290 |
Why?
|
| Clinical Decision-Making | 3 | 2019 | 533 | 0.280 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 686 | 0.250 |
Why?
|
| Heart Rate | 2 | 2018 | 762 | 0.240 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 3859 | 0.240 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 4980 | 0.240 |
Why?
|
| Aged, 80 and over | 8 | 2023 | 30940 | 0.240 |
Why?
|
| Angiopoietin-like Proteins | 2 | 2022 | 13 | 0.240 |
Why?
|
| RNA, Small Interfering | 2 | 2020 | 2214 | 0.220 |
Why?
|
| Interleukin-18 | 1 | 2023 | 91 | 0.220 |
Why?
|
| Administration, Intravenous | 1 | 2024 | 251 | 0.220 |
Why?
|
| Fishes | 1 | 2023 | 55 | 0.220 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 4495 | 0.210 |
Why?
|
| Postmenopause | 2 | 2020 | 380 | 0.200 |
Why?
|
| Proprotein Convertase 9 | 1 | 2022 | 68 | 0.200 |
Why?
|
| Radial Artery | 1 | 2022 | 44 | 0.200 |
Why?
|
| Infusions, Intravenous | 1 | 2024 | 1437 | 0.190 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 48 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 2364 | 0.190 |
Why?
|
| Lipoprotein-X | 1 | 2020 | 3 | 0.190 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2020 | 43 | 0.180 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2022 | 177 | 0.180 |
Why?
|
| Coronary Thrombosis | 1 | 2020 | 42 | 0.180 |
Why?
|
| Telecommunications | 1 | 2020 | 26 | 0.180 |
Why?
|
| Behavioral Risk Factor Surveillance System | 4 | 2021 | 61 | 0.180 |
Why?
|
| Vitamin K | 1 | 2020 | 55 | 0.180 |
Why?
|
| Antifibrinolytic Agents | 1 | 2020 | 38 | 0.180 |
Why?
|
| Tobacco Use | 1 | 2020 | 64 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 111 | 0.180 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 562 | 0.180 |
Why?
|
| Prognosis | 5 | 2023 | 22452 | 0.170 |
Why?
|
| Angina Pectoris | 1 | 2019 | 68 | 0.170 |
Why?
|
| Protective Factors | 1 | 2020 | 108 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 114 | 0.170 |
Why?
|
| Vaping | 1 | 2020 | 42 | 0.170 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 99 | 0.170 |
Why?
|
| Echocardiography | 2 | 2023 | 1240 | 0.170 |
Why?
|
| Oligonucleotides | 1 | 2020 | 245 | 0.170 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 77 | 0.170 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 29 | 0.170 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 261 | 0.170 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 6 | 0.160 |
Why?
|
| Tobacco Products | 1 | 2020 | 123 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 3394 | 0.160 |
Why?
|
| Heart Ventricles | 2 | 2021 | 846 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2023 | 1076 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2021 | 356 | 0.160 |
Why?
|
| Office Visits | 1 | 2019 | 95 | 0.160 |
Why?
|
| Radiation Exposure | 1 | 2019 | 74 | 0.160 |
Why?
|
| Hereditary Central Nervous System Demyelinating Diseases | 1 | 2018 | 18 | 0.160 |
Why?
|
| RNAi Therapeutics | 1 | 2019 | 44 | 0.160 |
Why?
|
| Multidetector Computed Tomography | 1 | 2019 | 148 | 0.160 |
Why?
|
| Guideline Adherence | 2 | 2019 | 643 | 0.160 |
Why?
|
| Paraplegia | 1 | 2018 | 99 | 0.150 |
Why?
|
| Animals | 7 | 2023 | 62801 | 0.150 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 108 | 0.150 |
Why?
|
| Prospective Studies | 3 | 2023 | 13361 | 0.150 |
Why?
|
| Mutation | 1 | 2018 | 15859 | 0.150 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 435 | 0.150 |
Why?
|
| Phenotype | 2 | 2020 | 6464 | 0.150 |
Why?
|
| Hypertriglyceridemia | 1 | 2019 | 114 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2020 | 316 | 0.150 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 247 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 256 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 565 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 580 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 413 | 0.140 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2019 | 401 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 499 | 0.140 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 4329 | 0.140 |
Why?
|
| Membrane Transport Proteins | 1 | 2018 | 243 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 321 | 0.140 |
Why?
|
| Cysts | 1 | 2018 | 208 | 0.140 |
Why?
|
| Monocytes | 1 | 2020 | 787 | 0.140 |
Why?
|
| Inflammasomes | 1 | 2018 | 165 | 0.140 |
Why?
|
| RNA Interference | 1 | 2020 | 1398 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 256 | 0.130 |
Why?
|
| Cause of Death | 1 | 2019 | 783 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2020 | 532 | 0.130 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 405 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 471 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 548 | 0.120 |
Why?
|
| Testosterone | 1 | 2020 | 733 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 2019 | 643 | 0.120 |
Why?
|
| Radiation Dosage | 1 | 2019 | 1043 | 0.120 |
Why?
|
| Action Potentials | 1 | 2018 | 596 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2019 | 2286 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 1060 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 737 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 747 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2020 | 1346 | 0.120 |
Why?
|
| Lipoproteins | 2 | 2022 | 231 | 0.120 |
Why?
|
| Aging | 1 | 2022 | 1576 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 868 | 0.110 |
Why?
|
| Adolescent | 5 | 2021 | 32508 | 0.110 |
Why?
|
| Adult | 10 | 2021 | 81540 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 5103 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2019 | 2466 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2018 | 1669 | 0.100 |
Why?
|
| Young Adult | 3 | 2020 | 22035 | 0.100 |
Why?
|
| Time Factors | 3 | 2021 | 13103 | 0.100 |
Why?
|
| Patient Selection | 1 | 2019 | 2040 | 0.100 |
Why?
|
| Population Groups | 1 | 2010 | 39 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2020 | 1618 | 0.090 |
Why?
|
| Genotype | 1 | 2018 | 4111 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2018 | 2958 | 0.080 |
Why?
|
| Prevalence | 3 | 2022 | 3409 | 0.080 |
Why?
|
| Incidence | 1 | 2019 | 5837 | 0.080 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 21 | 0.080 |
Why?
|
| Child | 2 | 2020 | 30343 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2018 | 9430 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 15239 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 2432 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 1546 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 2254 | 0.050 |
Why?
|
| Genome, Human | 1 | 2010 | 1834 | 0.050 |
Why?
|
| Apolipoprotein C-III | 1 | 2022 | 36 | 0.050 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 46 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2018 | 16919 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 64 | 0.050 |
Why?
|
| Geography | 1 | 2020 | 139 | 0.050 |
Why?
|
| Diastole | 1 | 2020 | 189 | 0.040 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 16 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 264 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2018 | 12206 | 0.040 |
Why?
|
| Lisinopril | 1 | 2019 | 29 | 0.040 |
Why?
|
| Amlodipine | 1 | 2019 | 24 | 0.040 |
Why?
|
| Metoprolol | 1 | 2019 | 27 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2019 | 97 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 4326 | 0.040 |
Why?
|
| Rats | 1 | 2008 | 6639 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 104 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 5897 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 291 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 163 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2020 | 578 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 1211 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 503 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 351 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 593 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 429 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 1031 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 2189 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2018 | 1834 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2019 | 604 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 1522 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 2109 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2020 | 39679 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1669 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 3536 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 1229 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2018 | 4990 | 0.020 |
Why?
|
| Human Genome Project | 1 | 2010 | 67 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5485 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 5780 | 0.020 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2009 | 17 | 0.020 |
Why?
|
| Absorption | 1 | 2009 | 81 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6185 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2009 | 122 | 0.020 |
Why?
|
| Cricetinae | 1 | 2009 | 792 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 723 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 320 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 1369 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2009 | 526 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 3679 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 3123 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 36026 | 0.010 |
Why?
|